Hill A - Search Results

1

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.

Lanzafame M, Lattuada E, Rigo F, Hill A, Vento S. Lanzafame M, et al. Among authors: hill a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19822. doi: 10.7448/IAS.17.4.19822. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397566 Free PMC article.

2

Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

Hill A, Miralles D, Vangeneugden T, Lefebvre E. Hill A, et al. AIDS. 2007 Jul 31;21(12):1651-3. doi: 10.1097/QAD.0b013e3282703593. AIDS. 2007. PMID: 17630565

3

Raltegravir: is a 400 mg once-daily dose enough?

Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Lanzafame M, et al. Among authors: hill a. J Antimicrob Chemother. 2010 Mar;65(3):595-7. doi: 10.1093/jac/dkp488. Epub 2010 Jan 12. J Antimicrob Chemother. 2010. PMID: 20071368 No abstract available.

4

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E. Hill AM, et al. Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182345 Clinical Trial.

5

The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.

Hill AM, Cho M, Mrus JM. Hill AM, et al. AIDS Rev. 2011 Jan-Mar;13(1):41-8. AIDS Rev. 2011. PMID: 21412388 Review.

6

Optimizing HIV treatment.

Hill A. Hill A. Curr Opin HIV AIDS. 2013 Jan;8(1):34-40. doi: 10.1097/COH.0b013e32835b7f28. Curr Opin HIV AIDS. 2013. PMID: 23143139 Review.

7

Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up.

Lanzafame M, Lattuada E, Rigo F, Ferrari A, Hill A, Vento S. Lanzafame M, et al. Among authors: hill a. J Antimicrob Chemother. 2015 Feb;70(2):627-30. doi: 10.1093/jac/dku390. Epub 2014 Oct 8. J Antimicrob Chemother. 2015. PMID: 25298517 No abstract available.

8

Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018.

Hill A, Hill T, Jose S, Pozniak A. Hill A, et al. Among authors: hill t. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19497. doi: 10.7448/IAS.17.4.19497. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394006 Free PMC article.

9

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.

Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A. Antinori A, et al. Among authors: hill a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19525. doi: 10.7448/IAS.17.4.19525. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394034 Free PMC article.

10

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor.

Barber T, Hill A, Singh GJ, Boffito M, Nelson M, Moyle G. Barber T, et al. Among authors: hill a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19562. doi: 10.7448/IAS.17.4.19562. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394069 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,368 results

Search Page